INJECTA 36, fill-finish solution for high-speed RTU processing
Pharmaceutical manufacturers and CDMOs need flexible solutions to face the pace of today’s evolving markets.
Time-to-market must be reduced and a company must be able to handle a wide range of product types and packaging formats, such as vials, syringes, and cartridges. Modularity helps to play a role in allowing for scale-up and down without process re-qualification. And together with these aspects, no one can ignore the need to comply with strict industry guidelines.
Unrivalled technologies for a comprehensive solution, in line with Annex 1 INJECTA 36 answers these issues with the highly advanced technologies. A high-performance, aseptic fill-finish concept, INJECTA pioneers the use of advanced robotics to minimise human intervention. Flexibility, high containment, scalability, modularity and compliance are the backbone of the solution, strictly adhering to GMP requirements as detailed in Annex 1, answering the most challenging aspects for high-speed filling, such as the management of direct/indirect contact parts, adherence to the first air principle, and proper handling of incoming/outgoing materials in the aseptic area. RTU components are handled using automatic, no-touch, un-bagging methods or with systems such as NEBULA, IMA Life’s continuous high-speed decontamination tunnel.
Robots designed specifically for aseptic environments
Exploiting six-axis robotic handling technologies, INJECTA 36 is the world’s most efficient high-speed processing solution for RTU components, particularly syringes and cartridges.
With increased flexibility and minimal cross-contamination risks, the robots are programmed to adapt to different containers and adjust processing speeds, something previous machines were unable to cope with effectively. Up to 36,000 nested syringes/hour INJECTA 36 is the high-speed version able to handle 36,000 nested syringes per hour, ensuring processing accuracy with statistical weight control or 100% IPC for up to 6,500 pcs/hr. Perfectly suited to isolation technology or containment solutions, INJECTA allows for a reduced isolator shell width, for a compact footprint. It features automatic weight cell calibration without operator intervention and downstream connection with automatic plunger presence inspection and single non-conformity rejection.
The performance achieved by INJECTA 36 is now enabling pharmaceutical companies to reduce their time-tomarket, especially for vaccines and key pharmaceuticals.
INJECTA won BEST IN SHOW at the Interphex 2023 Exhibitor Awards.
For further information, visit:
